Financial Counselors Inc. boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 108,596 shares of the conglomerate’s stock after buying an additional 1,200 shares during the quarter. Financial Counselors Inc.’s holdings in Danaher were worth $9,315,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in DHR. ETRADE Capital Management LLC raised its holdings in shares of Danaher by 5.1% in the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares in the last quarter. Honeywell International Inc. acquired a new stake in shares of Danaher in the 2nd quarter valued at $25,317,000. Roundview Capital LLC raised its holdings in shares of Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares in the last quarter. Eastern Bank raised its holdings in shares of Danaher by 4,291.1% in the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock valued at $10,802,000 after purchasing an additional 125,086 shares in the last quarter. Finally, Perkins Coie Trust Co raised its holdings in shares of Danaher by 2.0% in the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock valued at $2,484,000 after purchasing an additional 586 shares in the last quarter. Institutional investors own 76.32% of the company’s stock.
In other Danaher news, CFO Daniel L. Comas sold 88,184 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the transaction, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at approximately $20,735,812.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of the firm’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the transaction, the chief accounting officer now directly owns 18,314 shares in the company, valued at $1,678,661.24. The disclosure for this sale can be found here. Insiders have sold a total of 273,810 shares of company stock worth $25,218,813 over the last three months. 12.20% of the stock is currently owned by insiders.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same period last year, the firm posted $0.87 EPS. Danaher’s revenue for the quarter was up 9.6% on a year-over-year basis. research analysts anticipate that Danaher Corporation will post 3.99 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s payout ratio is currently 16.52%.
A number of equities research analysts have recently weighed in on DHR shares. J P Morgan Chase & Co restated an “overweight” rating and issued a $95.00 price objective on shares of Danaher in a report on Friday, September 8th. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 price objective on shares of Danaher in a report on Tuesday, September 26th. Cowen reiterated a “buy” rating and set a $90.00 price target on shares of Danaher in a research note on Wednesday, October 4th. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a research note on Thursday, October 5th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $95.00 price target (up from $86.00) on shares of Danaher in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $93.31.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).
What are top analysts saying about Danaher Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Danaher Corporation and related companies.